NIH's Science Bridge Meeting: Translating Boredom into Bulletins
Published Date: 3/31/2025
Notice
Summary
The National Center for Advancing Translational Sciences is holding a public meeting on April 17, 2025, to review grant applications and share updates. Scientists and organizations applying for grants will be affected, with some discussions kept private to protect sensitive info. You can watch the open session online and send your comments within 15 days after the meeting.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 0 costs, 1 mixed.
Grant Applications Will Be Reviewed
Scientists and organizations that submitted grant applications will have their applications reviewed and evaluated on April 17, 2025. The meeting agenda lists "To review and evaluate grant applications," so applicants should note that their submissions will be considered on that date.
Closed Sessions Protect Confidential Info
Part of the April 17, 2025 meeting (11:00 a.m. to 12:30 p.m.) will be closed to protect confidential trade secrets, commercial property (such as patentable material), and personal information about individuals associated with grant applications. Applicants' sensitive technical or personal information may be discussed only in that closed session.
Public Can Watch and Submit Comments
The meeting's Open Session on April 17, 2025 (1:00 p.m. to 3:00 p.m.) may be accessed by the public via the NIH Videocast at https://videocast.nih.gov, and any interested person may file written comments by sending a statement to the contact person no later than 15 days after the meeting. Comments must include name, address, telephone number, and business or professional affiliation when applicable.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14980, Government Owned Invention Available for License: Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration
The National Eye Institute has a cool new invention using special peptides to help protect eyes from inherited diseases like retinitis pigmentosa, which causes vision loss for over 100,000 Americans. They’re looking for partners to help develop easy-to-use eyedrops or gene therapy to slow down or stop this eye damage. This could bring hope and new treatments to many people with few options, and interested parties can start talking to the NIH now!
Previous / Next Documents
Previous: 2025-05475, Center for Scientific Review; Amended Notice of Meeting
The NIH’s Center for Scientific Review updated a meeting about infectious diseases happening May 1-2, 2025. They changed the contact person from Dr. Zheng to Dr. Lewis. The meeting is still closed to the public, so only invited experts will join—no money or timing changes here, just a quick contact switch!
Next: 2025-05477, Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Meeting
The Eunice Kennedy Shriver National Institute of Child Health & Human Development is holding a virtual meeting on June 9-10, 2025, to discuss important health research and review grant applications. This meeting affects researchers and organizations seeking funding, with some sessions open to the public and others closed to protect privacy. No new funding changes are announced, but grant reviews could impact future research support.